UnitedHealth Group Valuation Back in Focus After Beating Earnings

UnitedHealth Group (UNH) has reported Q2 2026 results that beat revenue and adjusted EPS forecasts. The company's improved adjusted operating margin was supported by lower medical costs, while full-year earnings guidance was raised.

The stock has eased in the past month with a 30-day share price return of -5.48%, but still shows positive momentum year-to-date with a 20.57% return and a 1-year total shareholder return of 53.21%. Over the long term, however, 3- and 5-year total shareholder returns are more muted.

The company's valuation is now back in focus, as it appears to be a solid operator after Q2 despite its recent share price pause. Investors may be wondering if they're paying too much for the quality on offer, or if the current price still represents a reasonable value.